Teva Suspends Sales of Zecuity Migraine Patch

Sumatriptan transdermal system can cause burns and scarring

Teva Pharmaceuticals has decided to temporarily suspend sales, marketing, and distribution of its Zecuity sumatriptan iontophoretic transdermal system, or migraine patch, to investigate the cause of burns and scars associated with the product. The FDA has advised health care professionals to discontinue prescribing Zecuity. Patients should stop using any remaining patches and contact their prescribers for an alternative migraine medication.


Our most popular topics on Managedcaremag.com